Squarepoint Ops LLC decreased its holdings in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 53.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,194 shares of the company's stock after selling 57,451 shares during the period. Squarepoint Ops LLC owned 0.21% of UroGen Pharma worth $535,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the business. Renaissance Technologies LLC purchased a new position in UroGen Pharma during the fourth quarter valued at approximately $1,472,000. Lazard Asset Management LLC purchased a new position in UroGen Pharma during the fourth quarter valued at approximately $67,000. Janus Henderson Group PLC purchased a new position in UroGen Pharma during the fourth quarter valued at approximately $149,000. ProShare Advisors LLC purchased a new position in UroGen Pharma during the fourth quarter valued at approximately $137,000. Finally, Bank of New York Mellon Corp grew its stake in UroGen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock valued at $1,001,000 after acquiring an additional 6,430 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently commented on URGN. Scotiabank began coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price objective for the company. The Goldman Sachs Group reduced their price objective on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Guggenheim reduced their price objective on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 23rd. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective for the company. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.14.
View Our Latest Stock Analysis on UroGen Pharma
UroGen Pharma Price Performance
UroGen Pharma stock traded up $0.22 during mid-day trading on Thursday, hitting $5.14. 1,478,779 shares of the company traded hands, compared to its average volume of 741,278. UroGen Pharma Ltd. has a one year low of $3.42 and a one year high of $20.70. The stock has a market cap of $236.99 million, a price-to-earnings ratio of -1.63 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The stock has a fifty day moving average price of $8.86 and a 200-day moving average price of $10.24.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. On average, equities analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.
About UroGen Pharma
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
